Sunita Zalani
Conseiller Juridique Général chez Intarcia Therapeutics, Inc.
Profil
Sunita Zalani is currently the Vice President-Global Regulatory Affairs & Quality at Intarcia Therapeutics, Inc. Prior to her current position, she worked as the Executive Director-Global Regulatory Affairs at Amgen, Inc. from 2004 to 2012.
She also worked as the Vice President-Global Regulatory Affairs at Onyx Pharmaceuticals, Inc. and as a Global Regulatory Lead at Eli Lilly & Co. Dr. Zalani holds a doctorate degree from the University of Baroda.
Postes actifs de Sunita Zalani
| Sociétés | Poste | Début |
|---|---|---|
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Conseiller Juridique Général | 05/08/2014 |
Anciens postes connus de Sunita Zalani
| Sociétés | Poste | Fin |
|---|---|---|
| AMGEN INC. | Conseiller Juridique Général | 01/05/2012 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Conseiller Juridique Général | - |
Formation de Sunita Zalani
| University of Baroda | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Entreprise privées | 2 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
